An interventional study of Hysteroscopy for diagnosis and treatment of pregnancy of unknown location in Pregnancy of Unknown Location, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Diagnostic
Infertility patients have a higher baseline risk of ectopic pregnancy compared to the general population. If an early pregnancy is not visible by ultrasound, patients with a pregnancy of unknown location (PUL) will undergo uterine aspiration (D\&C) in order to diagnose an ectopic pregnancy and/or treat an abnormal intrauterine pregnancy destined for miscarriage. If the pathologic specimen obtained after D\&C does not contain chorionic villi, the presumptive diagnosis of ectopic pregnancy is made and methotrexate therapy is typically recommended. In many institutions, a D\&C must be scheduled in the operating room so that it may be performed under anesthesia, potentially delaying the urgent treatment of ectopic pregnancy.
Office hysteroscopy is a safe and well-tolerated means of evaluating the uterine cavity, though little literature exists supporting its use in the evaluation of PUL. The objective of this study is to compare hysteroscopic biopsy to the gold standard D\&C for the diagnosis and treatment of PUL. The investigators propose a prospective study including patients undergoing care at the University of Pennsylvania. Patients will be included if they have at least three bHCG values demonstrating a \<50% increase in over 48 hours. A hysteroscopy with possible biopsy followed by uterine aspiration will be performed, and the final pathology results will be compared. Although pathology results from the procedure are considered the gold standard of diagnosis, physicians typically do not wait for results to return before proceeding with necessary treatment. Instead, all patients will have a serum bHCG drawn on post-operative day 1, and those with a \<50% decrease compared to pre-procedural values will undergo treatment with methotrexate therapy per institutional protocol.
The findings from this pilot study will inform future research comparing hysteroscopic vs. D\&C for management of PUL. If hysteroscopic targeted biopsy is more accurate than D\&C in detecting an abnormal IUP, this technique could reduce unnecessary methotrexate exposure in patients with abnormal IUPs. If adapted to the office setting, hysteroscopic biopsy could also shorten time to diagnosis and definitive treatment. In addition, targeted treatment in the office setting could lower the rate of intrauterine adhesions, and may improve overall the patient experience.
221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.
This study's planned enrollment of 60 is below the median of 150 across 120 interventional studies indexed under Abortion, Spontaneous.
Browse Abortion, Spontaneous studies →University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 235 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 109 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients in this study will have a diagnostic hysteroscopy with possible biopsy of abnormal pregnancy tissue prior to dilation and curettage
Diagnostic Test: Hysteroscopy for diagnosis and treatment of pregnancy of unknown location
All patients in this trial will have a diagnostic hysteroscopy performed prior to a dilation and curettage in the treatment of their pregnancy of unknown location
Presence or absence of abnormal tissue within the endometrial cavity
Intra-operative photographs will be taken of the participants uterine cavities at five standardized locations (left cornua, right cornua, anterior uterine wall, posterior uterine wall, and entire uterine cavity at level of internal os). The presence or absence of abnormal tissue will be documented, and findings qualitatively compared between the cavities of participants with the final diagnosis of non-viable intrauterine pregnancy and an ectopic pregnancy.
Time frame: From enrollment to 1 week post-operatively
Sensitivity of hysteroscopy compared to gold-standard dilation and curettage
Sensitivity, specificity, and positive and negative predictive values of hysteroscopic biopsy as a diagnostic test will be compared to that of D\&C. Statistical significance will be determined with the use of Fisher exact test analysis with Stata software, with a probability value of \<0.05 considered statistically significant
Time frame: From enrollment to 1 week post-operatively
Specificity of hysteroscopy compared to gold-standard dilation and curettage
Specificity of hysteroscopic biopsy as a diagnostic test will be compared to that of D\&C. Statistical significance will be determined with the use of Fisher exact test analysis with Stata software, with a probability value of \<0.05 considered statistically significant
Time frame: From enrollment to 1 week post-operatively
Positive predictive value of hysteroscopy compared to gold-standard dilation and curettage
Positive predictive value of hysteroscopic biopsy as a diagnostic test will be compared to that of D\&C. Statistical significance will be determined with the use of Fisher exact test analysis with Stata software, with a probability value of \<0.05 considered statistically significant
Time frame: From enrollment to 1 week post-operatively
Negative predictive value of hysteroscopy compared to gold-standard dilation and curettage
Negative predictive value of hysteroscopic biopsy as a diagnostic test will be compared to that of D\&C. Statistical significance will be determined with the use of Fisher exact test analysis with Stata software, with a probability value of \<0.05 considered statistically significant
Time frame: From enrollment to 1 week post-operatively
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.